JP2018508569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508569A5 JP2018508569A5 JP2017559779A JP2017559779A JP2018508569A5 JP 2018508569 A5 JP2018508569 A5 JP 2018508569A5 JP 2017559779 A JP2017559779 A JP 2017559779A JP 2017559779 A JP2017559779 A JP 2017559779A JP 2018508569 A5 JP2018508569 A5 JP 2018508569A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- conr
- alkylene
- pharmaceutical composition
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910005965 SO 2 Inorganic materials 0.000 claims description 81
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 34
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 33
- 230000032683 aging Effects 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 7
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 70
- 150000002431 hydrogen Chemical class 0.000 description 20
- 229910052717 sulfur Inorganic materials 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 0 CC(C)[n](c(C)c1S(C)(=O)=O)c(-c(cc2)ccc2Cl)c1-c1cc(F)cc(N(CC2)CCN2c(cc2)ccc2NS(c(cc2*)ccc2N[C@](CCN(CC2)CCC2C(OCCCP(O)(O)=O)=O)CSc2ccccc2)(=O)=O)c1 Chemical compound CC(C)[n](c(C)c1S(C)(=O)=O)c(-c(cc2)ccc2Cl)c1-c1cc(F)cc(N(CC2)CCN2c(cc2)ccc2NS(c(cc2*)ccc2N[C@](CCN(CC2)CCC2C(OCCCP(O)(O)=O)=O)CSc2ccccc2)(=O)=O)c1 0.000 description 5
- -1 1,2,3,4-oxatriazolyl Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031023 Oral submucosal fibrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000005207 oral submucous fibrosis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113227P | 2015-02-06 | 2015-02-06 | |
| US62/113,227 | 2015-02-06 | ||
| PCT/US2016/016894 WO2016127135A1 (en) | 2015-02-06 | 2016-02-05 | Compounds and uses in treatment of senescence-associated conditons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018508569A JP2018508569A (ja) | 2018-03-29 |
| JP2018508569A5 true JP2018508569A5 (https=) | 2019-03-14 |
Family
ID=56564790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559779A Pending JP2018508569A (ja) | 2015-02-06 | 2016-02-05 | 老化関連状態の治療における化合物および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170266211A1 (https=) |
| EP (1) | EP3253387A4 (https=) |
| JP (1) | JP2018508569A (https=) |
| CN (1) | CN108025006A (https=) |
| AU (1) | AU2016215035A1 (https=) |
| CA (1) | CA2981753A1 (https=) |
| HK (1) | HK1249030A1 (https=) |
| WO (1) | WO2016127135A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US20200354336A9 (en) * | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| AU2018357829B2 (en) | 2017-12-30 | 2019-09-26 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| KR20200108301A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN117866015A (zh) | 2018-04-30 | 2024-04-12 | 联合生物科技公司 | 一种临床管理中使用的化合物及其用途 |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| US11026963B2 (en) * | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20210379078A1 (en) * | 2018-10-30 | 2021-12-09 | Unity Biotechnology, Inc. | Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor |
| US11872237B2 (en) * | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| WO2021030655A1 (en) * | 2019-08-15 | 2021-02-18 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating hypertensive disorders |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021132628A1 (ja) * | 2019-12-26 | 2021-07-01 | 東レ株式会社 | 酸化セリウムのナノ粒子、分散体、酸化剤、抗酸化剤および酸化セリウムのナノ粒子の製造方法 |
| WO2021204060A1 (en) * | 2020-04-10 | 2021-10-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Combinations of bcl-2/bcl-xl inhibitors and related uses |
| CN113929715A (zh) * | 2020-07-13 | 2022-01-14 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式 |
| WO2022022706A1 (en) * | 2020-07-31 | 2022-02-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating lung diseases |
| CN114073703B (zh) * | 2020-08-21 | 2022-12-30 | 苏州亚盛药业有限公司 | 用于治疗非酒精性脂肪肝炎的组合物和方法 |
| KR20230145313A (ko) * | 2020-11-10 | 2023-10-17 | 유니티 바이오테크놀로지, 인크. | Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법 |
| EP4649499A1 (en) * | 2023-01-12 | 2025-11-19 | Koninklijke Philips N.V. | Model-guided imaging for mechanical ventilation |
| WO2024164543A1 (zh) * | 2023-02-09 | 2024-08-15 | 中山大学附属第八医院（深圳福田） | [1,2,4]三唑并[4,3-b]哒嗪衍生物在衰老及衰老相关性疾病防治中的应用 |
| CN115837022B (zh) * | 2023-02-20 | 2023-04-25 | 中山大学附属第八医院（深圳福田） | 1,2,4三唑并4,3-b哒嗪衍生物在制备抗衰老药物中的应用 |
| EP4719408A1 (en) * | 2023-05-30 | 2026-04-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6228873B1 (en) * | 1994-12-09 | 2001-05-08 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| EP2668180B1 (en) * | 2011-01-25 | 2018-08-01 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| EP3689886A1 (en) * | 2013-01-16 | 2020-08-05 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer |
| RU2015149680A (ru) * | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w |
| IL286427B2 (en) * | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
-
2016
- 2016-02-05 WO PCT/US2016/016894 patent/WO2016127135A1/en not_active Ceased
- 2016-02-05 JP JP2017559779A patent/JP2018508569A/ja active Pending
- 2016-02-05 HK HK18108744.2A patent/HK1249030A1/zh unknown
- 2016-02-05 EP EP16747391.7A patent/EP3253387A4/en not_active Withdrawn
- 2016-02-05 AU AU2016215035A patent/AU2016215035A1/en not_active Abandoned
- 2016-02-05 CA CA2981753A patent/CA2981753A1/en not_active Abandoned
- 2016-02-05 CN CN201680020353.5A patent/CN108025006A/zh active Pending
-
2017
- 2017-06-01 US US15/611,589 patent/US20170266211A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/899,401 patent/US20200338097A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508569A5 (https=) | ||
| CN108025006A (zh) | 化合物及在治疗衰老相关病症中的用途 | |
| AU2025220854A1 (en) | Compositions and methods for the treatment of Liver Disorders | |
| JP5827328B2 (ja) | リン酸輸送を阻害する化合物及び方法 | |
| JP6770511B2 (ja) | 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター | |
| RU2013122834A (ru) | Соединения, композиции и способы, подходящие для мобилизации холестерина | |
| RU2016134429A (ru) | Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением | |
| JP2014500243A5 (https=) | ||
| JP2012502980A5 (https=) | ||
| EP0986376A1 (fr) | INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE | |
| BRPI0909564B8 (pt) | uso de um composto | |
| JP2010536815A (ja) | 制御性ｔ細胞の活性化方法 | |
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| HUE025443T2 (en) | New piperidinyl monocarboxylic acids as S1P1 receptor agonists | |
| IL256329A (en) | Carbazole derivatives for the treatment of fibrotic diseases, symptoms and related conditions | |
| EP3706744B1 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| JP2024514597A5 (https=) | ||
| Coelho et al. | A guide to transthyretin amyloidosis | |
| CN112654355A (zh) | 用于骨骼肌调节的raf-1激酶抑制剂化合物、其方法和用途 | |
| JP2021533170A (ja) | チアミン誘導体を含む血管又は弁膜石灰化の予防又は治療用の組成物 | |
| WO2010149654A1 (en) | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt | |
| JP2021533158A (ja) | 治療の実施方法 | |
| WO2020160619A1 (en) | A glycation reducing composition and method of use thereof | |
| WO2025183868A1 (en) | Novel pharmacological mechanism to block stress-induced cortisol production | |
| JP7338877B2 (ja) | 心臓アセチルコリン産生能誘導薬 |